Take a look at our previous reports:

Our JAK1 program with GLPG0555 in OA

GLPG0555 is a proprietary JAK1 inhibitor currently being evaluated in a randomized, double-blind, placebo-controlled Phase 1b study with readout in 2022. The primary objectives of the study include safety and tolerability of single intra-articular doses of GLPG0555 in healthy volunteers. Secondary objectives include the pharmacokinetics and pharmacodynamics of GLPG0555.

GLPG0555
A JAK1 inhibitor currently in Phase 1b in osteoarthritis